Instituto Nacional de Neurología y Neurocirugía, SSA, Laboratorio de Investigaciones Clínicas, Insurgentes Sur 3877, Col. La Fama, México, DF 14269, México.
Trans R Soc Trop Med Hyg. 2010 Apr;104(4):243-50. doi: 10.1016/j.trstmh.2010.01.005. Epub 2010 Jan 29.
Human neurocysticercosis (NC) is endemic in most countries of Latin America, Asia and Africa and is re-emerging in some industrialized nations. Both within and among endemic countries, NC is very variable in its clinical and radiological features, as well as in the intensity of the immuno-inflammatory reactions of the hosts. This review, focusing on the Mexican experience, describes and interprets the heterogeneity of NC as the result of different combinations among factors associated with the parasite, host and environment. The review may serve to foster similar descriptive efforts in other endemic areas of the world in order to facilitate the identification of the distinct factors that participate in the complex pathogenesis and diverse clinical outcomes of NC. In particular, it is necessary to understand the precise physiopathology of the inflammatory reaction associated with NC, as inflammation is one of the characteristics of those NC cases that are clinically more severe and less responsive to current treatments. Devising new medical interventions through the use of molecular regulators of the innate and adaptive immune responses of the host is a largely unexplored approach that could improve the existing forms of treatment.
人囊虫病（NC）在拉丁美洲、亚洲和非洲的大多数国家流行，并在一些工业化国家重新出现。在流行国家内部和之间，NC 在其临床和影像学特征以及宿主的免疫炎症反应强度方面存在很大差异。本综述侧重于墨西哥的经验，描述和解释了 NC 的异质性，这是寄生虫、宿主和环境相关因素的不同组合的结果。该综述可以促进在世界其他流行地区进行类似的描述性研究，以促进确定参与 NC 复杂发病机制和不同临床结果的不同因素。特别是，有必要了解与 NC 相关的炎症反应的确切病理生理学，因为炎症是临床更严重且对现有治疗反应较差的那些 NC 病例的特征之一。通过使用宿主固有和适应性免疫反应的分子调节剂来设计新的医疗干预措施是一种尚未得到充分探索的方法，它可以改进现有的治疗形式。
